Insulin-Like Growth Factor 1 Attenuates the Pro-Inflammatory Phenotype of Neutrophils in Myocardial Infarction

Bibliographic Details
Title: Insulin-Like Growth Factor 1 Attenuates the Pro-Inflammatory Phenotype of Neutrophils in Myocardial Infarction
Authors: Rianne Nederlof, Sophia Reidel, André Spychala, Stefanie Gödecke, André Heinen, Tobias Lautwein, Patrick Petzsch, Karl Köhrer, Axel Gödecke
Source: Frontiers in Immunology, Vol 13 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Immunologic diseases. Allergy
Subject Terms: insulin-like growth factor 1, myocardial infarction, neutrophil, signaling, inflammation, Immunologic diseases. Allergy, RC581-607
More Details: Acute myocardial infarction (MI) induces an extensive sterile inflammation, which is dominated in the early phase by invading neutrophils and monocytes/macrophages. The inflammatory response after MI critically affects infarct healing and cardiac remodeling. Therefore, modulation of cardiac inflammation may improve outcome post MI. Insulin-like growth factor 1 (IGF1) treatment reduces infarct size and improves cardiac function after MI via IGF1 receptor mediated signaling in myeloid cells. Our study aimed to investigate the effect of IGF1 on neutrophil phenotype both in vitro and in vivo after MI. We show that IGF1 induces an anti-inflammatory phenotype in bone marrow derived neutrophils. On the molecular and functional level IGF1 treated neutrophils were indistinguishable from those induced by IL4. Surprisingly, insulin, even though it is highly similar to IGF1 did not create anti-inflammatory neutrophils. Notably, the IGF1 effect was independent of the canonical Ras/Raf/ERK or PI3K/AKT pathway, but depended on activation of the JAK2/STAT6 pathway, which was not activated by insulin treatment. Single cell sequencing analysis 3 days after MI also showed that 3 day IGF1 treatment caused a downregulation of pro-inflammatory genes and upstream regulators in most neutrophil and many macrophage cell clusters whereas anti-inflammatory genes and upstream regulators were upregulated. Thus, IGF1 acts like an anti-inflammatory cytokine on myeloid cells in vitro and attenuates the pro-inflammatory phenotype of neutrophils and macrophages in vivo after MI. IGF1 treatment might therefore represent an effective immune modulatory therapy to improve the outcome after MI.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1664-3224
Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2022.908023/full; https://doaj.org/toc/1664-3224
DOI: 10.3389/fimmu.2022.908023
Access URL: https://doaj.org/article/ddfa61368cbc44b1ba436e2e13f4bc20
Accession Number: edsdoj.fa61368cbc44b1ba436e2e13f4bc20
Database: Directory of Open Access Journals
More Details
ISSN:16643224
DOI:10.3389/fimmu.2022.908023
Published in:Frontiers in Immunology
Language:English